Mirum is transforming rare liver disease momentum into a catalyst-rich commercial growth story with multiple shots on goal and a clearer path to profitability.
Mirum Pharmaceuticals Inc (MIRM) has successfully transitioned from a clinical-stage orphan disease developer into a high-growth, commercial-stage biopharmaceutical powerhouse.[1, 2] As of June 2026, the company is demonstrating exceptional commercial execution, led by its flagship ileal bile acid transporter (IBAT) inhibitor, LIVMARLI (maralixibat), and its established Bile Acid Medicines portfolio.[1, 2, 3] The company’s first-quarter 2026 financial results showcased a robust top-line performance with total net product sales reaching $159.9 million, representing a 43.3% year-over-year growth that exceeded the consensus forecast of $148.8 million by 7.46%.[4, 5] Based on this sustained commercial momentum, management raised its full-year 2026 net product sales guidance to a range of $660 million to $680 million.[4, 5]
This commercial progress is supported by a series of transformative business development moves and clinical triumphs.[5, 6] The strategic acquisition of Bluejay Therapeutics in January 2026 introduced brelovitug, a highly promising monoclonal antibody for Chronic Hepatitis Delta Virus (HDV).[6, 7] Concurrently, the in-licensing of zilurgisertib from Incyte in April 2026 provides an immediate commercial catalyst, with a Prescription Drug User Fee Act (PDUFA) action date set for September 26, 2026, in patients with Fibrodysplasia Ossificans Progressiva (FOP).[5, 8] Furthermore, the Phase 2b VISTAS trial of volixibat in Primary Sclerosing Cholangitis (PSC) met its primary endpoint with high statistical significance, positioning the company to file a New Drug Application (NDA) in the second half of 2026.[9, 10]
Financially, Mirum has structurally optimized its balance sheet through a massive $690 million zero-coupon convertible senior notes offering due 2032.[11] This structure was deployed to retire a portion of the company’s higher-yielding 4.00% convertible notes due 2029, resulting in reduced ongoing cash interest obligations and establishing a pro-forma cash cushion of over $420 million.[11, 12] While the GAAP net loss of -$798.8 million (GAAP EPS of -$13.43) in Q1 2026 initially triggered investor caution, this loss was driven entirely by non-recurring, non-cash in-process research and development (IPR&D) charges of $726.3 million and stock-based compensation of $34.7 million tied to the Bluejay transaction.[5, 13]
This analysis maintains a Buy rating on MIRM with a 12-month target price of $135.00 per share, implying an attractive upside from its current trading level of $114.97.[14] The core investment thesis centers on the underappreciated operating leverage of the expanding commercial footprint, a highly de-risked late-stage pipeline with major near-term regulatory readouts, and a capital structure designed to fund the company to GAAP profitability by 2028.[6]
Mirum’s commercial engine relies on two distinct pillars: the IBAT franchise and the Bile Acid Medicines portfolio.[2, 5] LIVMARLI continues to serve as the primary growth vehicle, generating $113.8 million in net product sales in Q1 2026, representing a 55.5% increase compared to the $73.2 million recorded in Q1 2025.[5, 15] Growth is primarily driven by deep penetration into the Progressive Familial Intrahepatic Cholestasis (PFIC) market, where Mirum holds a roughly 50% market share split with its direct competitor, Bylvay (marketed by Ipsen/Albireo).[3, 16] Expansion into adult and adolescent PFIC populations via genetic testing has unlocked a substantial prevalent patient base that was previously undiagnosed.[3] In the Alagille Syndrome (ALGS) market, LIVMARLI remains the dominant therapeutic choice, with approximately 50% penetration of the addressable U.S. prevalent population.[3]
The second pillar, the Bile Acid Medicines portfolio (comprising Cholbam and Chenodal/Ctexli), was acquired from Travere Therapeutics in late 2023.[17] This high-margin business generated $46.1 million in Q1 2026, registering 20.1% year-over-year growth.[5, 15] The commercial execution here is highly efficient, utilizing a specialized rare genetics field force that continues to identify patients suffering from Cerebrotendinous Xanthomatosis (CTX) and single-enzyme defects.[6, 17] The recent FDA approval of CTEXLI (chenodiol) for CTX in early 2025 has further diversified this revenue stream.[15, 18]
To accelerate the penetration of these key markets, the commercial leadership has initiated a major sales force expansion.[6] The U.S. liver field team is on track to triple from 20 to approximately 60 personnel by early 2027.[6] This targeted expansion will scale the company’s commercial reach from 1,500 to over 4,000 liver healthcare providers across both pediatric and adult specialties, capturing the vast majority of potential prescribers in the United States.[6] Management estimates that the peak sales potential for LIVMARLI exceeds $1.0 billion, with the upcoming Phase 3 EXPAND indication representing approximately one-third of this opportunity.[3, 6]
The pipeline is designed to target rare liver and genetic diseases with high unmet clinical needs.[2] The table below outlines the core pipeline assets, clinical stage, anticipated milestones, and competitive landscape:
| Compound | Class / Mechanism | Target Indication | Current Phase | Anticipated Catalyst / Date | Peer Competitors |
|---|---|---|---|---|---|
| Volixibat | Oral IBAT Inhibitor | Primary Sclerosing Cholangitis (PSC) [9] | Phase 2b (VISTAS) [9] | NDA Submission: H2 2026 [9] | No approved U.S. therapies [10] |
| Volixibat | Oral IBAT Inhibitor | Primary Biliary Cholangitis (PBC) [10] | Phase 2b (VANTAGE) [10] | Topline Data: Q1 2027 [10] | Iqirvo (Ipsen), Ocaliva (Intercept) |
| Brelovitug | Anti-HBsAg IgG1 mAb | Chronic Hepatitis Delta (HDV) [7] | Phase 3 (AZURE-1 & 4) [7] | 24-Week Topline: H2 2026 [7] | Hepcludex (Gilead Sciences) [19] |
| Zilurgisertib | Oral ALK2 Inhibitor | Fibrodysplasia Ossificans Progressiva [8] | Phase 2 (PROGRESS) [8] | PDUFA Date: Sept 26, 2026 [5] | Sohonos (Ipsen) |
| MRM-3379 | PDE4D Inhibitor | Fragile X Syndrome [20] | Phase 2 [20] | Ongoing Enrollment [20] | Shionogi, Zynerba |
Primary Sclerosing Cholangitis is a chronic cholestatic liver disease characterized by progressive bile duct scarring and intense, debilitating pruritus.[9, 21] In May 2026, the clinical team presented late-breaking results from the global, randomized, double-blind, placebo-controlled Phase 2b VISTAS trial at the European Association for the Study of the Liver (EASL) Congress.[9, 22] The study met its primary endpoint, demonstrating that a 20 mg twice-daily (BID) dose of volixibat achieved a statistically significant and clinically meaningful placebo-adjusted reduction in cholestatic pruritus on the Adult Itch Reported Outcome (ItchRO) scale over 28 weeks.[10, 22]
The table below summarizes the key efficacy outcomes from the primary analysis cohort (moderate-to-severe itch, $n=111$) of the VISTAS trial:
| Clinical Parameter (At Week 28) | Volixibat 20 mg BID ($n=54$) | Placebo ($n=57$) | Treatment Difference | p-value |
|---|---|---|---|---|
| LS Mean Change in Adult ItchRO | -2.72 [10] | -1.08 [10] | -1.64 [10] | $p < 0.0001$ [10] |
| Responders ($\geq 2$-Point ItchRO Reduction) | 55.6% [10] | 26.3% [10] | 29.3% [10] | $p = 0.0019$ [10] |
| Responders ($\geq 3$-Point ItchRO Reduction) | 37.0% [9] | 11.0% [9] | 26.0% [9] | $p = 0.0011$ [9] |
| LS Mean Change in Serum Bile Acids | -33.7 $\mu$mol/L [10] | +2.1 $\mu$mol/L [10] | -35.8 $\mu$mol/L [10] | $p = 0.0324$ [10] |
| PROMIS Sleep Disturbance Score Change | Improved [9] | Minimal Change | -5.69 (adjusted) [9] | $p = 0.0011$ [9] |
Volixibat’s safety profile was consistent with the known class effects of systemic ileal bile acid transporter inhibition.[9, 10] Across the full trial population ($n=158$), treatment-emergent adverse events (TEAEs) occurred in 93.5% of volixibat patients compared to 84.0% for placebo, with grade 3 or higher events reported in 13.0% and 11.1% respectively.[22] Serious adverse events occurred in 10.4% of the active arm versus 6.2% of the placebo arm, while premature discontinuations due to adverse events stood at 9.1% versus 2.5%.[22] Notably, discontinuations due to diarrhea—the most common gastrointestinal side effect—were limited to 3.9% of volixibat-treated patients.[22] Given that there are currently no approved therapies for PSC-related pruritus in the United States, volixibat is positioned as a highly viable therapeutic candidate, with a pre-NDA meeting scheduled for summer 2026 and an NDA submission planned for the second half of 2026.[9, 10, 22]
Hepatitis Delta is the most severe and rapidly progressive form of chronic viral hepatitis, occurring exclusively as a co-infection in patients carrying the Hepatitis B virus (HBV).[7, 23] The acquisition of Bluejay Therapeutics integrated brelovitug (BJT-778), a high-potency, pan-genotypic, fully human IgG1 monoclonal antibody targeting the Hepatitis B surface antigen (HBsAg), into the late-stage pipeline.[6, 7]
The clinical rationale for brelovitug is supported by its multiple mechanisms of action: it neutralizes infectious HBV and HDV virions, clears HBsAg-containing subviral particles, and forms immune complexes that activate antigen-specific T cells.[7, 24] In a Phase 2 study of chronic HDV patients, brelovitug monotherapy achieved a 100% virologic response rate (defined as a $\geq 2 \log_{10}$ HDV RNA reduction or target not detected) across all tested doses (300 mg weekly, 600 mg weekly/bi-weekly, and 900 mg monthly).[25, 26]
The table below highlights the dose-dependent Week 48 results from this pivotal Phase 2 trial:
| Dosing Cohort | Virologic Response | Undetectable HDV RNA | Combined Response (Virologic + ALT Normalization) |
|---|---|---|---|
| 300 mg Weekly (QW) ($n=18$) | 100% [26] | 44% [26] | 65% ($n=11/17$) [26] |
| 600 mg QW / Bi-Weekly (Q2W) ($n=11$) | 100% [26] | 30% [26] | 75% ($n=3/4$) [26] |
| 900 mg Monthly (Q4W) ($n=18$) | 100% [26] | 39% [26] | 82% ($n=14/17$) [26] |
The antibody demonstrated a highly favorable safety and tolerability profile, with no adverse events of grade 3 or higher, no serious adverse events, and no treatment discontinuations due to side effects.[25, 26] Enrollment in the registrational Phase 3 AZURE-1 study and screening for the Phase 3 AZURE-4 study are complete.[7] Both studies are evaluating a composite primary endpoint of combined virologic and biochemical (ALT) response at Week 24, aligned with the FDA’s accelerated approval pathway.[7] Topline 24-week data are expected in the second half of 2026, establishing a clear path toward a Biologics License Application (BLA) submission in 2027.[6, 7]
In April 2026, Mirum secured the exclusive global development and commercialization rights to zilurgisertib from Incyte, adding an advanced genetic medicine to its portfolio.[5, 8] Zilurgisertib is an oral, once-daily, small-molecule inhibitor of the activin receptor-like kinase 2 (ALK2) receptor, which is abnormally hyperactive in FOP patients and drives progressive, abnormal bone formation in soft tissues (heterotopic ossification, or HO).[8, 27] Under the licensing agreement, Incyte received a $16 million upfront payment and is eligible for a $25 million milestone upon FDA approval, alongside sales-based milestones and mid-to-high-single-digit royalties.[6] Incyte also retains ownership of any rare pediatric disease Priority Review Voucher (PRV) if awarded.[6]
The pivotal Phase 2 PROGRESS study presented at the ENDO 2026 conference on June 14, 2026, demonstrated a consistent and durable treatment effect.[28, 29] Cohort 1 evaluated zilurgisertib 100 mg once daily in 63 adolescents and adults (aged $\geq 12$ years) randomized 1:1 against placebo for 24 weeks, followed by an open-label extension to Week 48.[28, 29] At Week 24, active treatment resulted in an 81% reduction in the number of patients developing new HO lesions ($p = 0.0986$) and a 99.9% reduction in the total volume of new HO lesions (nominal $p < 0.0001$).[28, 29] Furthermore, zilurgisertib-treated patients experienced a net reduction in existing HO lesion volume, whereas placebo patients showed an increase (nominal $p = 0.004$).[29, 30] During the open-label extension, no new HO lesions were observed through Week 48 among patients who continued active treatment or those who crossed over from placebo.[28, 30]
The FDA accepted Incyte’s NDA for zilurgisertib under Priority Review, establishing a PDUFA action date of September 26, 2026.[5] If approved, Mirum will immediately assume operational control and launch the drug by the end of 2026.[6] FOP is an ultra-rare disease affecting approximately 300 patients in the United States and 900 globally, representing a highly concentrated market where care is localized in a small number of specialized centers.[6, 8] Management expects global peak sales for zilurgisertib to exceed $200 million.[6]
Mirum’s Q1 2026 financial results reflect a company aggressively deploying capital to construct a late-stage rare disease pipeline.[5, 6] Total net product sales reached $159.9 million, a 43.3% increase compared to $111.6 million in Q1 2025, driven by a 55.5% expansion of the LIVMARLI franchise.[5] However, the company recorded a GAAP net loss of -$798.8 million, translating to a GAAP EPS of -$13.43, which missed the consensus forecast of -$0.34 by a wide margin.[4, 13]
This significant EPS miss was entirely due to one-time, non-recurring expenses tied to the acquisition of Bluejay Therapeutics.[4, 6] Total operating expenses for the quarter reached $949.3 million, which included $726.3 million in non-cash, in-process research and development (IPR&D) charges, and $34.7 million in non-recurring stock-based compensation directly associated with the transaction.[5] Excluding these non-recurring acquisition items and standard non-cash expenses, ongoing R&D expenses were $73.7 million (including $20.8 million allocated to brelovitug development), and SG&A expenses were $63.4 million.[5]
The table below provides a detailed comparison of the Q1 2026 financial performance against Q1 2025:
| Financial Metric (USD in thousands) | Quarter Ended March 31, 2025 | Quarter Ended March 31, 2026 | Year-over-Year Change (%) |
|---|---|---|---|
| LIVMARLI U.S. Net Sales | $50,200 (est.) | $84,000 [6] | +67.3% |
| LIVMARLI International Net Sales | $23,000 (est.) | $30,000 [6] | +30.4% |
| LIVMARLI Total Net Sales | $73,200 [15] | $113,800 [5] | +55.5% |
| Bile Acid Medicines Net Sales | $38,400 [15] | $46,100 [5] | +20.1% |
| Total Net Product Revenues | $111,600 [5] | $159,900 [5] | +43.3% |
| Cost of Sales | $18,200 (est.) | $22,100 (net of amort.) [5] | +21.4% |
| Research & Development (R&D) | $41,200 (est.) | $73,700 (ex-SBC) [5] | +78.9% |
| Selling, General & Administrative (SG&A) | $38,500 (est.) | $63,400 (ex-SBC) [5] | +64.7% |
| Non-Recurring IPR&D Charge | $0 | $726,300 [5] | NM |
| Total Operating Expenses | $126,800 [5] | $949,300 [5] | +648.7% |
| GAAP Net Loss | -$15,200 (est.) | -$798,841 [13] | NM |
| Unrestricted Cash & Investments | $292,800 (Dec 31, 2024) [31] | $420,600 (Mar 31, 2026) [5] | +43.6% (15-month increase) |
Crucially, at the product level, Mirum operates with high margins, maintaining a cash contribution margin in the mid-50% range.[6] Operating cash flow was positive at approximately $2.0 million for the quarter.[6] This operational cash-flow positivity demonstrates that the commercial platform is self-sustaining, covering baseline development costs before accounting for strategic transaction cash outflows.[6]
In May 2026, Mirum completed a $690.0 million zero-coupon convertible senior notes offering due 2032 in a private 144A placement, which included the full exercise of the initial purchasers' $90.0 million overallotment option.[11] The estimated net proceeds from the offering were approximately $671.6 million.[11]
The structural mechanics and dilutive parameters of this debt instrument are summarized below:
| Convertible Note Parameter | Terms and Stated Details |
|---|---|
| Aggregate Principal Issued | $690.0 million [11] |
| Stated Interest Rate | 0.00% (Zero-Coupon; no accretion of principal) [11, 32] |
| Final Maturity Date | June 1, 2032 [11, 32] |
| Initial Conversion Rate | 7.1971 shares of common stock per $1,000 principal [11, 32] |
| Implied Conversion Price | Approximately $138.94 per share [11, 32] |
| Conversion Premium | 30.0% over the May 12, 2026 closing price of $106.88 [11, 32] |
| Maximum Conversion Rate | 9.3562 shares per $1,000 principal (upon certain corporate events) [11] |
| Maximum Shares Issuable | 6,455,778 shares of common stock [11] |
| Allocation of Proceeds | $475.0 million cash + 3,220,529 common shares used to retire $237.2 million principal of outstanding 4.00% convertible senior notes due 2029 [11] |
This capital restructuring is highly strategic. By utilizing a zero-coupon structure, Mirum eliminated the annual interest payments associated with the retired portion of its 2029 notes.[11] This transaction extends the debt maturity profile out to 2032 while preserving cash to support clinical milestones.[11, 33] The remaining proceeds, combined with the $420.6 million cash balance as of March 31, 2026, provide the company with a substantial liquidity buffer.[5, 20]
To value Mirum’s diversified commercial and clinical portfolio, a sum-of-the-parts risk-adjusted Net Present Value (rNPV) model was constructed. A Weighted Average Cost of Capital (WACC) of 10.0% was applied to all future cash flows, alongside conservative, industry-standard probability-of-success adjustments for the clinical assets.
The components of this valuation model are detailed below:
Combining these components yields a total enterprise value of $7.62 billion and an implied equity value of $7.75 billion. Based on a fully diluted share count of approximately 57.4 million shares (which accounts for options and restricted stock units but excludes the out-of-the-money 2032 convertible notes), the intrinsic value is estimated at $135.00 per share. This target price represents a justified valuation, supported by a commercial business growing at over 40% year-over-year and multiple high-probability late-stage clinical assets.[4, 5]
While Mirum’s clinical pipeline is highly advanced, several key development risks remain. The planned H2 2026 NDA submission for volixibat in PSC depends on a favorable safety profile.[9, 10] In the VISTAS Phase 2b study, elevations in liver enzymes (ALT, AST, ALP) and bilirubin were observed more frequently in volixibat-treated patients than in the placebo group.[9, 10] Because PSC is characterized by baseline fluctuations in liver biochemistry due to mechanical strictures, the FDA will closely examine these safety data to ensure these elevations do not indicate drug-induced liver injury (DILI).[22] Any regulatory delays or requirements for additional safety studies would push back the expected 2027/2028 commercial launch timeline.[35]
In the chronic HDV segment, the competitive landscape changed on May 22, 2026, when the FDA granted accelerated approval to Gilead Sciences' Hepcludex (bulevirtide-gmod) 8.5 mg, making it the first approved therapy for HDV in the United States.[19, 37] Gilead possesses a massive global commercial footprint, significant financial resources, and an established hepatology commercial team.[37, 38] While brelovitug has demonstrated highly competitive Phase 2 efficacy data (up to 82% combined response and a more convenient weekly or monthly dosing schedule compared to bulevirtide's daily injection), Mirum will face a well-entrenched competitor upon market entry.[25, 26, 37]
In the pediatric cholestatic space, Ipsen’s Bylvay remains a direct competitor to LIVMARLI.[3, 16] If Ipsen engages in aggressive discounting or secures exclusive formulary positions with major commercial payers, LIVMARLI’s market share and pricing leverage in PFIC could be compressed.[16]
The $690 million convertible senior notes offering due 2032 introduces potential dilution and technical trading pressures.[11] While the initial conversion price of $138.94 is 20.8% above the current stock price, the notes could eventually convert into up to 6,455,778 shares of common stock, representing approximately 10.6% dilution to existing shareholders.[11, 14]
Additionally, convertible note offerings often attract hedge funds practicing convertible arbitrage.[32] These institutional investors typically buy the convertible debt and concurrently short the underlying common stock to hedge their equity exposure.[32] This short-selling activity can create near-term technical pressure on the stock price, independent of the company’s fundamental performance.[32, 39]
As a commercial-stage orphan drug company, Mirum is highly sensitive to changes in reimbursement and drug-pricing policies.[40] Rare disease therapies command premium pricing due to very small patient populations.[6, 8] Under the Inflation Reduction Act (IRA) and ongoing healthcare reforms in the United States, payers are increasingly scrutinizing high-cost specialty drugs. If commercial insurers or government programs impose strict price caps, demand discount agreements, or limit reimbursement for orphan drugs that expand into secondary indications, the company's long-term margin profile could be impacted.[3, 41]
To evaluate Mirum’s risk-reward profile over a longer horizon, three potential operational and commercial paths have been modeled out to 2031:
| Financial & Operational Metric | Bear Case (15% Probability) | Base Case (60% Probability) | Bull Case (25% Probability) |
|---|---|---|---|
| 2031 Projected Revenues | $620 Million | $1.35 Billion | $1.95 Billion |
| LIVMARLI Sales Growth | Sales plateau at $450 million due to intense pricing competition from Bylvay and limited penetration of the EXPAND indication.[3, 16] | Steady growth to $750 million, driven by solid international adoption and successful expansion into the EXPAND pediatric basket.[3, 6] | Robust growth to $1.10 billion, with LIVMARLI capturing 70% of the global ALGS and PFIC markets and expanding into adult cholestatic pruritus.[1, 3] |
| Bile Acid Medicines | Revenues flat at $170 million due to slow identification of new CTX patients.[6] | Revenues grow to $220 million, supported by steady CTEXLI adoption in the United States.[15, 16] | Revenues reach $280 million, driven by successful expansion into international CTX markets.[15, 31] |
| Volixibat Progress | Volixibat fails to secure FDA approval in PSC due to liver safety signals, and the PBC program is discontinued.[9, 10] | Approved in PSC in late 2027; launches successfully to reach $200 million in sales by 2031.[22, 35] | Approved in both PSC and PBC; launches as the primary therapy for cholestatic pruritus, reaching $350 million in sales.[9, 10] |
| Brelovitug Progress | Phase 3 trials show marginal efficacy over placebo; the program is delayed or restricted to a narrow patient subset.[7] | Approved in late 2027; captures a 40% market share in HDV, generating $180 million in high-margin product sales.[6, 7] | Approved with a superior clinical label; quickly becomes the market leader over Hepcludex, generating $420 million in sales.[7, 19] |
| Zilurgisertib Launch | Receives a Complete Response Letter (CRL) or faces safety restrictions that limit uptake to less than 50 patients.[8] | Approved on September 26, 2026; achieves steady adoption to generate $120 million in revenues by 2031.[5, 6] | Approved with Priority Review; rapid commercial uptake in the United States and Europe, generating $180 million in sales.[5, 6] |
| GAAP Profitability Year | Profitability delayed beyond 2031 due to pipeline setbacks and elevated cash burn.[4] | GAAP profitability achieved in 2028, in line with long-term management guidance.[6] | GAAP profitability achieved early in 2027, driven by high operating leverage and rapid commercial execution.[4, 6] |
| Implied Share Valuation | $55.00 per share | $135.00 per share | $210.00 per share |
To complement the quantitative valuation, a qualitative scorecard was developed to rate Mirum's operational capabilities relative to its biotechnology peers. Each category is rated on a 1-to-5 scale:
The table below provides a detailed view of the executive leadership team, their roles, and their direct compensation structures:
| Executive Officer | Title / Role | Stated Yearly Compensation | Key Operational Responsibility |
|---|---|---|---|
| Chris Peetz | Chief Executive Officer & Director [42] | $10,441,224 (7.2% salary, 92.8% equity & bonuses) [42] | Overall strategic direction, corporate development, and financing execution.[4, 32] |
| Peter Radovich | President & Chief Operating Officer [42] | $3,960,000 [42] | Oversight of global commercial operations and the U.S. sales force expansion.[6] |
| Eric Bjerkholt | Chief Financial Officer [42] | $3,250,000 [42] | Financial planning, capital structure optimization, and debt management.[5, 11] |
| Joanne M. Quan, M.D. | Chief Medical Officer [42] | $3,589,334 [43] | Oversight of global clinical development and regulatory filings (NDA/BLA).[7, 10] |
| Lara Longpre | Chief Development Officer [42] | $1,510,000 [42] | Operational execution of clinical trial programs and investigator site management.[42, 44] |
Oversight of executive compensation shows alignment with shareholder value, as 92.8% of the CEO's compensation is tied to equity performance and milestones.[42] Recent insider trading activity shows that CEO Chris Peetz exercised options to acquire 30,000 shares at a low strike price of $2.936 and subsequently sold them under a pre-arranged Rule 10b5-1 trading plan adopted on March 2, 2026.[45, 46] This transaction was part of standard equity-based compensation management.[42] Following these trades, Mr. Peetz continues to hold a significant equity stake, consisting of 224,309 common shares held directly, 187,500 shares held indirectly through the Peetz Family Trust, and 128,487 outstanding options, maintaining strong alignment with long-term performance.[45]
Mirum Pharmaceuticals Inc represents a highly compelling, risk-adjusted investment opportunity within the mid-cap biotechnology sector. The market has occasionally mispriced the stock due to a focus on trailing GAAP earnings, which have been distorted by non-recurring, non-cash clinical acquisition charges rather than structural cash burn.[4, 5] At its core, the company has built a highly profitable, self-sustaining commercial business that is growing at over 40% year-over-year.[4, 6]
The core pillars of the investment thesis are:
Given the company’s commercial momentum, de-risked clinical pipeline, and robust balance sheet, Mirum Pharmaceuticals is an attractive candidate for long-term investors. A 12-month target price of $135.00 is supported by fundamental cash flows and the risk-adjusted value of its clinical assets.[47, 48]
Mirum’s stock has demonstrated notable relative strength, closing at $114.97 on June 24, 2026, which is adjacent to its all-time high of $114.97 and its 52-week high of $115.87.[14, 49] This upward trend reflects institutional accumulation following positive clinical updates for volixibat and brelovitug at the EASL Congress in late May 2026, alongside steady commercial performance.[9, 39] The stock’s 50-day simple moving average (SMA) currently sits at $96.06, while its 200-day SMA is at $74.57, indicating a well-established, long-term bullish trend.[47]
The stock’s daily price momentum is very strong, scoring 9.64 out of 10.00 and ranking 8th in momentum within the peer pharmaceutical industry group.[50] This momentum is supported by several short- and medium-term moving average indicators, which point to continued buying pressure:
The table below outlines the key technical support and resistance levels for MIRM:
| Technical Level | Price Point | Technical Stated Rationale |
|---|---|---|
| Major Resistance 2 | $125.36 [47] | Average analyst consensus price target; potential near-term target on a breakout.[47] |
| Major Resistance 1 | $115.87 [14, 49] | 52-week and all-time intraday high set on June 24, 2026; immediate breakout point.[14, 49] |
| Immediate Support 1 | $109.17 [14] | Intraday low from the June 24, 2026 trading session; immediate support on profit-taking.[14] |
| Major Support 1 | $96.06 [47] | 50-day simple moving average; key support zone during consolidation phases.[47] |
| Major Support 2 | $86.16 [50] | 200-day simple moving average; major long-term technical support.[50] |
The stock is currently testing resistance in the $115.00–$116.00 range.[49] A sustained close above $116.00 on above-average volume would confirm a technical breakout, likely driving the stock toward the next target range of $125.00 to $135.00.[47, 48] If there is a short-term pullback due to broader market consolidation, the stock has solid technical support at $109.17, followed by the 50-day SMA near $96.06.[14, 47] For short-term traders and tactical investors, accumulating shares on pullbacks toward the $100.00–$102.00 support level offers an attractive entry point ahead of the New Drug Application PDUFA date for zilurgisertib on September 26, 2026.[5, 49]
View Mirum Pharmaceuticals, Inc. (MIRM) stock page
Loading the interactive version of this report…